HaemoneticsvsMerck & Company

HAE and MRK stock compared: price, dividend, valuation and results, from SEC filings.

HAE

Haemonetics Corporation

$120.69

Value $5.5B

-0.54%
HAE's page

MRK

Merck & Company, Inc.

$143.40

Value $355B

-0.79%
MRK's page

Haemonetics (HAE) has a market value of $5.5B and Merck & Company (MRK) $355B. Over the last year, with dividends, HAE moved +64.2% and MRK +58.9%. The P/E is 52.8 for HAE and 144.5 for MRK. Dividend yield: HAE none, MRK 2.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    HAE$5.5B

    MRK$355B

    MRK is 65 times HAE

  • Revenue, 12 months

    HAE$1.4B

    MRK$67.4B

    MRK is 49 times HAE

  • Net income, 12 months

    HAE$104M

    MRK$2.5B

    MRK is 24 times HAE

  • Operating margin

    HAE12.8%

    MRK–

  • ROIC

    HAE6.3%

    MRK3.9%

    2.4 points apart

  • P/E

    HAE52.8

    MRK144.5

    MRK is 2.7 times HAE

  • Dividend yield

    HAE0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    HAE+103.1%

    MRK+98.6%

    4.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

HAE+103.1%

MRK+98.6%

10015020020222023202420252026
Returns by period
PeriodHAEWith dividendsMRKWith dividends
1 year since November 14, 2025+64.2%Price +64.2%+58.9%Price +54.3%
3 years since November 17, 2023+45.0%+13.2% a yearPrice +45.0%+54.5%+15.6% a yearPrice +40.9%
5 years since November 16, 2021+103.1%+15.2% a yearPrice +103.1%+98.6%+14.7% a yearPrice +70.5%
10 years since November 17, 2016+207.3%+11.9% a yearPrice +207.3%+225.2%+12.5% a yearPrice +139.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

HAEHaemoneticsMRKMerck & Company

Valuation

HAEMRK
Valuation
Price$120.69$143.40
Market value$5.5B$355B
Enterprise value (EV)$6.3B$399B
P/E52.8144.5
P/E, 5-year median36.914.8
P/B6.17.9
EV/EBIT35.983.7
Free cash flow yield5.4%4.2%

Results and growth

HAEMRK
Results and growth
Revenue, 12 months$1.4B$67.4B
Net income, 12 months$104M$2.5B
Free cash flow, 12 months$298M$14.7B
Earnings per share, 12 months$2.26$0.98
Revenue growth, year on year-2.0%1.3%
Revenue growth a year, past+8.9%over 5 years+9.4%over 5 years
EPS growth a year, past+5.8%over 5 years+21.2%over 5 years

Margins and returns on capital

HAEMRK
Margins and returns on capital
Gross margin59.6%71.8%
Operating margin12.8%–
Net margin7.5%3.6%
ROIC6.3%3.9%
ROE12.1%5.2%

Balance sheet

HAEMRK
Balance sheet
Cash$261M$9.7B
Total debt$1.1B$53.8B
Net debt / EBITDA3.05.7
Interest cover9.2×2.4×

Dividends and buybacks

HAEMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield3.2%1.4%
Shareholder yield3.2%3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: HAE or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Haemonetics or Merck & Company?

By market value, Merck & Company ($355B) is about 64.6 times Haemonetics ($5.5B), at today's prices.

How did HAE and MRK stock do over the last 10 years?

Since November 17, 2016, HAE's price moved +207.3% and MRK's +139.7%. With dividends: HAE +207.3% (+11.9% a year), MRK +225.2% (+12.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, HAE or MRK?

The dividend yield at today's price is none for Haemonetics and 2.37% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of HAE and MRK?

At today's price, the P/E is 52.8 for HAE and 144.5 for MRK. The median of the last five years was 36.9 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, Haemonetics or Merck & Company?

Over the last twelve months, the net margin was 7.5% for Haemonetics and 3.6% for Merck & Company, and the operating margin 12.8% and –. Revenue was $1.4B and $67.4B.

Which is the better investment, Haemonetics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.